Study tests pembrolizumab or nivolumab plus a diabetes-like drug
Treatments studied
Part of Cancer, Digestive system, Skin clinical trials.
This Phase 2 study tests whether adding a metabolic (diabetes-related) medicine to an immune therapy (pembrolizumab or nivolumab) can better control certain solid tumors. It may help people whose standard treatment would usually be pembrolizumab or nivolumab alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these cancers: melanoma, kidney (renal cell) cancer, lung (NSCLC), liver (HCC only if Child-Pugh A), MSI-high solid tumors, bladder (urothelial) cancer, stomach/GE junction cancer, or head/neck (HNSCC) cancer—and your usual treatment would be pembrolizumab or nivolumab alone.
- You must be able to get tumor biopsies before treatment and again after treatment using a core/surgical biopsy (a needle sample like FNA isn’t enough).
- You are 18 or older and can have trial treatment for as long as needed (good enough health/function; ECOG 0–2).
- Your scans must show at least one measurable spot of cancer that can be followed over time.
- You must have blood test and organ levels that are high enough/within limits (including good kidney function and certain liver/blood counts).
- You cannot have had prior anti–PD-1 or anti–PD-L1 antibody cancer treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a medicine injected directly into a tumor, alone or with pembrolizumab (an immune-therapy drug given through a vein). It is for people with advanced or metastatic solid cancers that have grown despite standard treatments, aiming to improve tumor control.
This trial tests an experimental oral drug (7HP349) combined with two immunotherapy drugs (ipilimumab and nivolumab) for people with advanced solid tumors. It aims to see if the combination is safe and effective in shrinking tumors.
This trial tests a combination of daily low-dose cyclophosphamide (a chemotherapy pill) and pembrolizumab (an immunotherapy) in people with advanced melanoma that has stopped responding to prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
This Phase 1/2 study tests the safety and early signs of benefit from CJRB-101 when combined with pembrolizumab (Keytruda) in people with advanced or metastatic lung, head and neck, or melanoma cancer. It may help some participants, but the main goal is to see how safe the combination is and whether it can control cancer.
This trial tests a lower dose of nivolumab (an immunotherapy drug) given less frequently to treat cancers that have spread or cannot be surgically removed. The goal is to see if this approach works well while reducing side effects compared to standard dosing.
This early-phase study tests a combination of three immune “checkpoint” medicines in people with advanced solid cancers. It aims to see how well they work and what side effects occur, including when given through a specific liver-focused treatment in eligible patients.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.